# Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

> **NCT04196205** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Nanchang University** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia ,Lymphomas

## Interventions

- **BIOLOGICAL:** Anti-CD19 CAR-T

## Key facts

- **NCT ID:** NCT04196205
- **Lead sponsor:** The First Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-08-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196205, "Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04196205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*